Table 1 Demographic, clinical course and outcome data of patients who acquired SBIs during the COVID-19 hospitalization
|  | All patients (n = 102) | Severe group (n = 33) | Critical group (n = 69) | P-value |
|---|---|---|---|---|
Characteristics | ||||
 Age, years | 66.2 (30 ~ 93) | 64.9 (30 ~ 82) | 66.1 (36 ~ 93) | 0.686 |
 Sex | 0.178 | |||
  Men | 68 (66.7%) | 19 (57.6%) | 49 (71.0%) |  |
  Women | 34 (33.3%) | 14 (42.4%) | 20 (29.0%) | |
Bacterial etiology | ||||
 A. baumanniia | 50 (49.0%) | 10 (30.3%) | 40 (58.0%) | 0.009 |
 CRABa | 47 (46.1%) | 9 (27.3%) | 38 (55.1%) | 0.008 |
 K. pneumoniaea | 35 (34.3%) | 6 (18.2%) | 29 (42.0%) | 0.018 |
 CRKPa | 32 (31.4%) | 5 (15.2%) | 27 (39.1%) | 0.015 |
Treatment before SBIs | ||||
 Antiviral therapy | 96 (94.1%) | 29 (87.9%) | 67 (97.1%) | 0.084 |
 Antibiotic therapy | 99 (97.1%) | 31 (93.9%) | 68 (98.6%) | 0.244 |
Outcomes | < 0.0001 | |||
 Discharge | 52 (51.0%) | 28 (84.8%) | 24 (34.8%) |  |
 Death | 50 (49.0%) | 5 (15.2%) | 45 (65.2%) | |